Rationale for anti-GITR cancer immunotherapy

European Journal of Cancer

Volumn 67, Issue , 2016, Pages 1-10

  Knee, Deborah A ^a   Hewes, Becker ^b   Brogdon, Jennifer L ^b  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Agonist; Cancer immunotherapy; GITR; TNFRSF18

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FC RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR LIGAND; LIGAND; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; DRUG TARGETING; HUMAN; IN VIVO STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR MODEL; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COLON TUMOR; COMBINATION DRUG THERAPY; DISEASE MODEL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, FC; T-LYMPHOCYTES, REGULATORY;

EID: 84984604984     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.06.028     Document Type: Review

References (80)

1. [1] Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., Sakaguchi, S., Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3 (2002), 135–142.
2. [2] Nocentini, G., Riccardi, C., GITR: a modulator of immune response and inflammation. Adv Exp Med Biol 647 (2009), 156–173.
3. [3] McHugh, R.S., Whitters, M.J., Piccirillo, C.A., Young, D.A., Shevach, E.M., Collins, M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002), 311–323.
4. [4] Krausz, L.T., Bianchini, R., Ronchetti, S., Fettucciari, K., Nocentini, G., Riccardi, C., GITR-GITRL system, a novel player in shock and inflammation. ScientificWorldJournal 7 (2007), 533–566.
5. [5] Khattri, R., Cox, T., Yasayko, S.A., Ramsdell, F., An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4 (2003), 337–342.
6. [6] Zhan, Y., Gerondakis, S., Coghill, E., Bourges, D., Xu, Y., Brady, J.L., et al. Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-kappaB and NFAT. J Immunol 181 (2008), 5405–5413.
7. [7] Hanabuchi, S., Watanabe, N., Wang, Y.H., Wang, Y.H., Ito, T., Shaw, J., et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 107 (2006), 3617–3623.
8. [8] Clouthier, D.L., Watts, T.H., Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev 25 (2014), 91–106.
9. [9] Petrillo, M.G., Ronchetti, S., Ricci, E., Alunno, A., Gerli, R., Nocentini, G., et al. GITR+ regulatory T cells in the treatment of autoimmune diseases. Autoimmun Rev 14 (2015), 117–126.
10. [10] Tone, M., Tone, Y., Adams, E., Yates, S.F., Frewin, M.R., Cobbold, S.P., et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A 100 (2003), 15059–15064.
11. [11] Kanamaru, F., Youngnak, P., Hashiguchi, M., Nishioka, T., Takahashi, T., Sakaguchi, S., et al. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 172 (2004), 7306–7314.
12. [12] Stephens, G.L., McHugh, R.S., Whitters, M.J., Young, D.A., Luxenberg, D., Carreno, B.M., et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 173 (2004), 5008–5020.
13. [13] Ronchetti, S., Zollo, O., Bruscoli, S., Agostini, M., Bianchini, R., Nocentini, G., et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 34 (2004), 613–622.
14. [14] Ronchetti, S., Nocentini, G., Bianchini, R., Krausz, L.T., Migliorati, G., Riccardi, C., Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells. J Immunol 179 (2007), 5916–5926.
15. [15] Snell, L.M., Lin, G.H., McPherson, A.J., Moraes, T.J., Watts, T.H., T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 244 (2011), 197–217.
16. [16] Snell, L.M., McPherson, A.J., Lin, G.H., Sakaguchi, S., Pandolfi, P.P., Riccardi, C., et al. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol 185 (2010), 7223–7234.
17. [17] Esparza, E.M., Lindsten, T., Stockhausen, J.M., Arch, R.H., Tumor necrosis factor receptor (TNFR)-associated factor 5 is a critical intermediate of costimulatory signaling pathways triggered by glucocorticoid-induced TNFR in T cells. J Biol Chem 281 (2006), 8559–8564.
18. [18] Lin, G.H., Snell, L.M., Wortzman, M.E., Clouthier, D.L., Watts, T.H., GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology. J Immunol 190 (2013), 4627–4639.
19. [19] Snell, L.M., Lin, G.H., Watts, T.H., IL-15-dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of IL-15. J Immunol 188 (2012), 5915–5923.
20. [20] Kim, I.K., Kim, B.S., Koh, C.H., Seok, J.W., Park, J.S., Shin, K.S., et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med 21 (2015), 1010–1017.
21. [21] Ronchetti, S., Ricci, E., Petrillo, M.G., Cari, L., Migliorati, G., Nocentini, G., et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res, 2015, 2015, 171520.
22. [22] Shevach, E.M., Stephens, G.L., The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?. Nat Rev Immunol 6 (2006), 613–618.
23. [23] van Olffen, R.W., Koning, N., van Gisbergen, K.P., Wensveen, F.M., Hoek, R.M., Boon, L., et al. GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol 182 (2009), 7490–7500.
24. [24] Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A.D., Colombo, M.P., Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105 (2005), 2845–2851.
25. [25] Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202 (2005), 885–891.
26. [26] Nishikawa, H., Kato, T., Hirayama, M., Orito, Y., Sato, E., Harada, N., et al. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 68 (2008), 5948–5954.
27. [27] Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16 (2010), 2781–2791.
28. [28] Bianchini, R., Bistoni, O., Alunno, A., Petrillo, M.G., Ronchetti, S., Sportoletti, P., et al. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. Eur J Immunol 41 (2011), 2269–2278.
29. [29] Watts, T.H., TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23 (2005), 23–68.
30. [30] Li, F., Ravetch, J.V., Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333 (2011), 1030–1034.
31. [31] Wilson, N.S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19 (2011), 101–113.
32. [32] Zhou, Z., Song, X., Berezov, A., Zhang, G., Li, Y., Zhang, H., et al. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci U S A 105 (2008), 5465–5470.
33. [33] Zhou, Z., Tone, Y., Song, X., Furuuchi, K., Lear, J.D., Waldmann, H., et al. Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci U S A 105 (2008), 641–645.
34. [34] Chattopadhyay, K., Ramagopal, U.A., Brenowitz, M., Nathenson, S.G., Almo, S.C., Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc Natl Acad Sci U S A 105 (2008), 635–640.
35. [35] Zhou, P., L'Italien, L., Hodges, D., Schebye, X.M., Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 179 (2007), 7365–7375.
36. [36] Ramirez-Montagut, T., Chow, A., Hirschhorn-Cymerman, D., Terwey, T.H., Kochman, A.A., Lu, S., et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176 (2006), 6434–6442.
37. [37] Cote, A.L., Zhang, P., O'Sullivan, J.A., Jacobs, V.L., Clemis, C.R., Sakaguchi, S., et al. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol 186 (2011), 275–283.
38. [38] Coe, D., Begom, S., Addey, C., White, M., Dyson, J., Chai, J.G., Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 59 (2010), 1367–1377.
39. [39] Xiao, X., Shi, X., Fan, Y., Zhang, X., Wu, M., Lan, P., et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun, 6, 2015, 8266.
40. [40] Hu, P., Arias, R.S., Sadun, R.E., Nien, Y.C., Zhang, N., Sabzevari, H., et al. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res 14 (2008), 579–588.
41. [41] Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S.M., Ettenberg, S., Knee, D.A., et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210 (2013), 1685–1693.
42. [42] Cohen, A.D., Schaer, D.A., Liu, C., Li, Y., Hirschhorn-Cymmerman, D., Kim, S.C., et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One, 5, 2010, e10436.
43. [43] Imai, N., Ikeda, H., Tawara, I., Wang, L., Wang, L., Nishikawa, H., et al. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression. Cancer Sci 100 (2009), 1317–1325.
44. [44] Cohen, A.D., Diab, A., Perales, M.A., Wolchok, J.D., Rizzuto, G., Merghoub, T., et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 66 (2006), 4904–4912.
45. [45] Nishioka, T., Nishida, E., Iida, R., Morita, A., Shimizu, J., In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules. Immunol Lett 121 (2008), 97–104.
46. [46] Kim, Y.H., Shin, S.M., Choi, B.K., Oh, H.S., Kim, C.H., Lee, S.J., et al. Authentic GITR signaling fails to induce tumor regression unless Foxp3+ regulatory T cells are depleted. J Immunol 195 (2015), 4721–4729.
47. [47] Stone, G.W., Barzee, S., Snarsky, V., Spina, C.A., Lifson, J.D., Pillai, V.K., et al. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol 13 (2006), 1223–1230.
48. [48] Stone, G.W., Barzee, S., Snarsky, V., Kee, K., Spina, C.A., Yu, X.F., et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 80 (2006), 1762–1772.
49. [49] Tolerx, Agonistic antibodies to human glucocorticoid-induced tumor necrosis factor receptor as potential stimulators of T cell immunity for the treatment of cancer and viral infections. Expert Opin Ther Pat 17 (2007), 567–575.
50. [50] Ponte, J.F., Ponath, P., Gulati, R., Slavonic, M., Paglia, M., O'Shea, A., et al. Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody. Immunology 130 (2010), 231–242.
51. [51] Schaer, D.A., Budhu, S., Liu, C., Bryson, C., Malandro, N., Cohen, A., et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 1 (2013), 320–331.
52. [52] Moody, G., Moriguchi, J., Sun, J.-R., McElroy, P., Tan, H., Bulliard, Y., et al. Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR. J Immunother Cancer, 3(Suppl. 2), 2015, P192.
53. [53] Tang, Y., Lou, J., Alpaugh, R.K., Robinson, M.K., Marks, J.D., Weiner, L.M., Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179 (2007), 2815–2823.
54. [54] Selby, M.J., Engelhardt, J.J., Quigley, M., Henning, K.A., Chen, T., Srinivasan, M., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1 (2013), 32–42.
55. [55] Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210 (2013), 1695–1710.
56. [56] Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N.S., Brogdon, J.L., OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 92 (2014), 475–480.
57. [57] Lu, L., Xu, X., Zhang, B., Zhang, R., Ji, H., Wang, X., Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 12 (2014), 36–47.
58. [58] Pedroza-Gonzalez, A., Zhou, G., Singh, S.P., Boor, P.P., Pan, Q., Grunhagen, D., et al. GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells. Oncoimmunology, 4, 2015, e1051297.
59. [59] Aida, K., Miyakawa, R., Suzuki, K., Narumi, K., Udagawa, T., Yamamoto, Y., et al. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-alpha gene therapy for pancreatic cancer. Cancer Sci 105 (2014), 159–167.
60. [60] Boczkowski, D., Lee, J., Pruitt, S., Nair, S., Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther 16 (2009), 900–911.
61. [61] Pruitt, S.K., Boczkowski, D., de Rosa, N., Haley, N.R., Morse, M.A., Tyler, D.S., et al. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 41 (2011), 3553–3563.
62. [62] Liu, Z., Tian, S., Falo, L.D. Jr., Sakaguchi, S., You, Z., Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther 17 (2009), 1274–1281.
63. [63] Fridman, W.H., Pages, F., Sautes-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12 (2012), 298–306.
64. [64] Becht, E., Giraldo, N.A., Germain, C., de Reynies, A., Laurent-Puig, P., Zucman-Rossi, J., et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol 130 (2016), 95–190.
65. [65] Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004), 942–949.
66. [66] Liu, C., Workman, C.J., Vignali, D.A., Targeting regulatory T cells in tumors. FEBS J 283 (2016), 2731–2748.
67. [67] Wainwright, D.A., Sengupta, S., Han, Y., Lesniak, M.S., Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 13 (2011), 1308–1323.
68. [68] Pedroza-Gonzalez, A., Verhoef, C., Ijzermans, J.N., Peppelenbosch, M.P., Kwekkeboom, J., Verheij, J., et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 57 (2013), 183–194.
69. [69] deLeeuw, R.J., Kost, S.E., Kakal, J.A., Nelson, B.H., The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18 (2012), 3022–3029.
70. [70] Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30 (2009), 899–911.
71. [71] Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid, Y., et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184 (2010), 3433–3441.
72. [72] Ladoire, S., Martin, F., Ghiringhelli, F., Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60 (2011), 909–918.
73. [73] Haas, M., Dimmler, A., Hohenberger, W., Grabenbauer, G.G., Niedobitek, G., Distel, L.V., Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol, 9, 2009, 65.
74. [74] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
75. [75] Jain, N., Nguyen, H., Chambers, C., Kang, J., Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A 107 (2010), 1524–1528.
76. [76] Ronchetti, S., Nocentini, G., Riccardi, C., Pandolfi, P.P., Role of GITR in activation response of T lymphocytes. Blood 100 (2002), 350–352.
77. [77] Gonzalez, A.M., Breous, E., Manrique, M.L., Savitsky, D., Waight, J., Gombos, R., et al. A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR. 2016, American Association for Cancer Research, Chicago, IL.
78. [78] Stewart, R.A., Tigue, N., Ireland, S., Hair, J., Bamber, L., Oberst, M., et al. MEDI1873: a novel hexameric GITRL fusion protein with potent agonistic and immunomodulatory activities in preclinical systems. 2016, American Association for Cancer Research, Chicago, IL.
79. [79] Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J.C., Zitvogel, L., Marabelle, A., Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 52 (2016), 50–66.
80. [80] Makkouk, A., Chester, C., Kohrt, H.E., Rationale for anti-CD137 cancer immunotherapy. Eur J Cancer 54 (2016), 112–119.